Last updated 2 weeks ago. Our resources are updated regularly but please keep in mind that links, programs, policies, and contact information do change.
A federal advisory panel reviewed whether to delay the Hepatitis B vaccine that has been given to American newborns for more than 30 years. The policy is credited with nearly eliminating the disease in children.
An advisory committee reconstituted under new leadership is reviewing the universally recommended birth dose. The review follows leadership changes at the Department of Health and Human Services.
The Political Push
Presidential Statements
President Donald Trump initiated discussion of the policy at a September 22, 2025 press conference. He claimed there is “no reason” to give newborns the Hepatitis B vaccine because the virus is primarily a sexually transmitted disease. Based on this premise, he stated the vaccine should wait until a child is “12 years old and formed.”
Trump also made claims about vaccines causing autism, called for removing aluminum and mercury from vaccines, and suggested splitting the MMR vaccine into separate shots. Medical experts disputed these statements, noting they represent a departure from previous administrations’ approach to scientific bodies.
New Leadership at HHS
Health and Human Services Secretary Robert F. Kennedy Jr. has a history of expressing concerns about vaccine safety that medical and scientific organizations say contradict scientific evidence. He removed the entire Advisory Committee on Immunization Practices (ACIP), the key federal panel that provides vaccine recommendations to the CDC, and replaced all 17 members with new appointees.
Kennedy appointed individuals, including Martin Kulldorff, a former Harvard professor whom he named as the new ACIP chair. Kulldorff had previously questioned whether every newborn needs the Hepatitis B vaccine.
This represented a significant change to a committee traditionally focused on scientific deliberation that now includes members who have questioned routine immunizations. Beyond Hepatitis B, Kennedy has also changed COVID-19 vaccine recommendations for children and ended federal funding for mRNA vaccine research.
The September ACIP Meeting
The reconstituted ACIP met on September 18-19, 2025, with the birth dose as a central topic. The committee considered a proposal to delay the first dose to at least one month of age for infants whose mothers tested negative for Hepatitis B surface antigen (HBsAg).
After discussion, the committee voted 11-to-1 to postpone the vote. The sole vote against postponing came from chair Martin Kulldorff. The postponement reflected procedural concerns. Members cited “inconsistencies in the wording,” ambiguity that could complicate clinical decisions, and questions about the one-month timeline.
The committee voted to recommend universal screening of pregnant women for Hepatitis B – which is already an existing standard of care. While this affirms current practice, it also provides support for the position of those who favor delay who argue that maternal screening is sufficient to identify at-risk infants. However, this approach does not address the concern that the universal birth dose exists as a “safety net” against screening failures.
Understanding Hepatitis B
The Virus
Hepatitis B attacks the liver and is highly contagious – up to 100 times more infectious than HIV. It causes both acute and chronic infection. The virus is often called a “silent epidemic” because many infected people, especially young children, show no symptoms. In the United States, up to 2.4 million people have chronic Hepatitis B, and two-thirds are unaware they’re infected.
Chronic infection can lead to cirrhosis, liver failure, and hepatocellular carcinoma. Chronic Hepatitis B is a primary cause of liver cancer worldwide. There is no cure.
The virus spreads through contact with infected blood and certain bodily fluids. While sexual contact and needle sharing are common adult transmission routes, they aren’t the only ones. The virus survives on surfaces for at least seven days, creating transmission risk through shared personal items like toothbrushes or razors, or in daycare settings.
Why Newborns Are Vulnerable
The risk of chronic Hepatitis B depends profoundly on age at infection. The most common transmission route globally is perinatal – from infected mother to baby during labor and delivery. An infant infected at birth or within the first year has a 90% chance of developing lifelong chronic infection. Of those chronically infected, roughly one in four will die prematurely from cirrhosis or liver cancer.
This risk is different for adults. Fewer than 10% of adults who contract Hepatitis B develop chronic infection. This extreme newborn vulnerability is why the public health strategy focuses on preventing infection as early as possible.
The birth dose, recommended within 24 hours of birth, functions as a multi-layered safety net. First, it acts as post-exposure prophylaxis, stimulating the infant’s immune system to fight off virus exposure during delivery. Second, it safeguards against maternal screening gaps – when pregnant women aren’t tested, tests produce errors, or women acquire infection late in pregnancy after screening. Third, it protects against “horizontal” transmission from infected (often asymptomatic) household members or caregivers.
Vaccination at birth addresses an asymmetrical risk: serious vaccine adverse events are exceedingly rare, while the risk of lifelong disease from infant infection is extraordinarily high.
Public Health Success
An earlier 1980s strategy vaccinating only “high-risk” adults did not succeed because it didn’t address virus spread among those without identified risk factors or perinatal and early childhood transmission. The ACIP recommended a new strategy in 1991: universal vaccination for all infants:
The results have been dramatic. Since implementing the universal birth dose:
- Acute Hepatitis B rates among U.S. children and adolescents declined by more than 99%.
- Between 1990 and 2002, reported cases in people under 19 fell by 89%, from 3.03 per 100,000 to just 0.34.
- The policy has virtually eliminated Hepatitis B among American children.
This approach isn’t unique to the United States. The World Health Organization and 117 other countries recommend a birth dose. No country that implemented such a policy has reversed it. The current U.S. discussion explores a targeted, risk-based approach that data from the 1980s showed was less effective.
Arguments for Delay
The Transmission Misconception
Trump and others have characterized Hepatitis B primarily as a sexually transmitted disease, arguing this makes the vaccine less relevant for newborns. Medical experts say this characterization is incomplete. While sexual contact is significant among adults, infants face two other transmission routes: perinatal (mother to child at birth) and horizontal (close contact with infected household members).
The Targeted Approach
Those favoring delay, including some new ACIP members, argue the vaccine should target “high-risk populations” – primarily infants born to HBsAg-positive mothers. This assumes maternal screening identifies every at-risk infant.
However, CDC data shows 12% to 16% of pregnant women in the U.S. have no record of Hepatitis B testing. Standard first-trimester screening misses infections acquired later in pregnancy. This approach provides no protection against infants contracting the virus from unknowingly infected family members or caregivers after birth. The suggestion by one ACIP memberthat physicians could determine household Hepatitis B status by asking the mother has been questioned by public health experts as insufficient for clinically sound public health strategy.
Safety Concerns
Trump’s comments about “pumping” a “vat of stuff” into a “delicate little body” reflect parental anxieties. Here are the facts:
Vaccine ingredients: Trump raised concerns about aluminum and mercury. The Hepatitis B vaccine contains no mercury or thimerosal preservative. It does contain a very small, safe amount of aluminum salt (typically aluminum hydroxide) functioning as an adjuvant – an ingredient used in vaccines for decades to create stronger, longer-lasting immune response. The aluminum amount is minimal and safe.
Debunked health links: Decades of research found have no evidence linking the Hepatitis B vaccine to autism, multiple sclerosis, or other autoimmune diseases.
Arguments Compared
| Argument for Delay | Proponent’s Rationale | Scientific & Public Health Evidence |
|---|---|---|
| Delay vaccine for infants of HBsAg-negative mothers | The virus is primarily sexually transmitted or spread via IV drug use; maternal screening sufficiently identifies risk. | Virus also spreads mother to child at birth and via household contact with unknowingly infected persons. Screening has gaps and misses cases; the birth dose serves as a critical safety net. |
| The vaccine is unnecessary for newborns | Newborns aren’t sexually active and some argue are “too fragile” for the vaccine. Some suggest the shot should wait until they are “12 years old.“ | Infants face the highest risk (90%) of developing chronic, lifelong infection if exposed. This risk drops dramatically with age. The vaccine is scientifically demonstrated to be safe and effective for newborns. |
| The vaccine contains harmful ingredients | Concerns about administering a vaccine containing aluminum and mercury to an infant. | The vaccine contains no mercury. It uses a tiny, safe amount of aluminum salt as adjuvant to improve immune response, a practice used safely for decades. The total volume is very small (0.5 mL). |
Medical Response
Professional Organizations
The review has met opposition from mainstream medical and public health organizations. This reflects the scientific evidence strength supporting current policy.
American Academy of Pediatrics (AAP): The AAP, representing 67,000 pediatricians, has voiced strong opposition. AAP President Dr. Susan Kressly said the September ACIP meeting “promoted false claims and misguided information**” in an “unprecedented effort to limit access to routine childhood immunizations and sow fear and mistrust.”** The organization maintains that the birth dose is a “critical safety net” and one of the “most important steps we can take to protect babies in their first 24 hours of life.”
In a significant step, the AAP published its own independent immunization schedule to ensure families and physicians have what it considers reliable, evidence-based guidance amid questions about federal deliberations. This departure from sole reliance on federal guidance is significant – it could lead to conflicting government and pediatric expert recommendations, which could complicate public health messaging in the future.
American College of Physicians and American Medical Association: Dr. Jason Goldman, representing the ACP, characterized the idea that Hepatitis B is confined to specific high-risk groups as “ignorant and uninformed.” The AMA expressed concern that ACIP’s recent process and recommendations “leave parents confused” and appear based on “reliance on selective data” rather than comprehensive evidence review.
Other Experts: Dr. John W. Ward, Director of the Coalition for Global Hepatitis Elimination and former CDC official, submitted formal statements to the ACIP urging it to maintain the universal birth dose, calling it safe, effective, and lifesaving against an “incurable, life-threatening infection.” Senator Bill Cassidy, MD (R-LA), a physician who treated patients with end-stage liver disease from Hepatitis B, has spoken publicly about the vaccine, using clinical experience to highlight severe, preventable suffering the birth dose prevents.
Potential National and Global Impact
The divergence between the medical establishment and the administration’s advisory panel could have significant consequences. If federal guidance is perceived as politically motivated and unreliable, states may increasingly develop their own public health laws and school immunization requirements independent of federal recommendations. This could create a patchwork of policies where child protection from preventable disease depends on location rather than unified, national, science-based standards.
Current U.S. policy aligns with global scientific consensus. The WHO recommends all infants receive their first Hepatitis B dose within 24 hours of birth. This recommendation is followed by 117 countries, none of which have reversed this policy. A change in U.S. policy would position the United States as an outlier, departing from established global practice.
The Vaccine
How It’s Made
The modern Hepatitis B vaccine contains no live virus and cannot cause Hepatitis B infection. It’s often called the world’s first “anti-cancer vaccine” because by preventing chronic viral infection, it directly prevents a leading cause of liver cancer.
The vaccine uses recombinant DNA technology. Scientists isolate the single gene from Hepatitis B virus that codes for a protein on its outer surface _ the Hepatitis B surface antigen (HBsAg). This gene is inserted into common baker’s yeast cells. The yeast produces large quantities of this single, harmless viral protein. The protein is harvested, purified, and becomes the vaccine’s active ingredient.
When injected, this protein teaches the immune system to recognize and create antibodies against the Hepatitis B virus surface, providing robust protection without exposing people to the virus itself. This process was designed to maximize safety by eliminating contamination risk from human blood products, a theoretical concern with the earliest 1980s vaccine version.
Safety Record
Since introduction, billions of doses have been administered worldwide, creating vast data confirming exceptional safety and effectiveness.
Efficacy: The vaccine is highly effective. When the full series is administered starting at birth, over 98% of healthy infants develop immunity that can last a lifetime. The vaccine is up to 95% effective at preventing mother-to-child transmission when given to infants of infected mothers along with Hepatitis B immune globulin (HBIG). Studies show immunity persists for at least 20 to 30 years.
Safety and Side Effects: The most common side effects are mild and temporary: soreness, redness, or swelling at the injection site, and occasionally low-grade fever. These are normal signs of the immune system building protection. Serious side effects are extremely rare. The most significant is anaphylaxis, estimated to occur in approximately 1 out of every 600,000 doses. This reaction is treatable, which is why people are typically observed for 15-30 minutes after receiving any vaccine.
Current Schedule
The current U.S. immunization schedule, long endorsed by the CDC and major medical organizations, provides protection at the earliest and most vulnerable life stage. The routine schedule for infants consists of three doses:
- Birth Dose: Within 24 hours of birth
- Second Dose: At age 1 to 2 months
- Third Dose: At age 6 to 18 months
This schedule is part of broader universal recommendations including vaccination for all unvaccinated children and adolescents under 19, all adults aged 19 through 59, and adults 60 and older with Hepatitis B infection risk factors.
Our articles make government information more accessible. Please consult a qualified professional for financial, legal, or health advice specific to your circumstances.